Strategic alliances

Bringing innovation faster to patients, together

By forming strategic alliances with pharmaceutical companies, we gain access to critical resources, expertise, and global reach,  to accelerate the development and potential commercialization of our innovations and bring life-changing therapies to patients faster.

10-year R&D agreement

Our collaboration with Gilead

Galapagos and Gilead have been collaborating since 2015 on the development and, later the commercialization, of filgotinib in inflammatory diseases. The companies expanded their collaboration in 2019 with a 10-year transformative research and development agreement, through which Gilead gained access to Galapagos’ innovative portfolio of compounds in preclinical and clinical development, as well as our proven drug discovery platform. Gilead has exclusive product license and option rights to develop and commercialize all current and future programs in all countries outside Europe.

Growing with Gilead

Expanded R&D capabilities and access to ex-European markets


year transformative R&D collaboration signed in 2019


seats on our Board of Directors


Investment in our company and our largest shareholder


Royalties on revenue outside Europe (only on revenues generated from products that have been opted-in by Gilead)

In 2020, Gilead and Galapagos amended the collaboration terms for the development and commercialization of filgotinib, now available in Europe and Japan for rheumatoid arthritis (RA) and ulcerative colitis (UC). The medicine is being advanced for other inflammatory diseases, to provide a broader commercialization role for Galapagos in Europe.

Under the amended agreement, Galapagos became the market authorization holder and is responsible for the commercialization of filgotinib in RA and UC providing the opportunity to build a commercial presence on an accelerated timeline.

Following the amended agreement with Gilead announced in October 2021, Galapagos will become the sole sponsor of the DIVERSITY trial of filgotinib in Crohn’s disease (CD) and the long-term extension study. The transfer was intended to be completed by 30 June 2022 and was completed by March 2023. Under the terms of the agreement, Gilead made a one-time payment of $15 million to Galapagos. From 1 April 2022, Galapagos is solely responsible for all development costs for DIVERSITY. In March 2022, Galapagos and Gilead agreed to transfer the sponsorship of the MANTA study and its LTE from Gilead to Galapagos, which transfer was largely completed by 31 December 2022.

All commercial economics on filgotinib in Europe transferred to us as of 1 January 2022, subject to payment of tiered royalties of 8 to 15 percent of net sales in Europe to Gilead, starting in 2024. Galapagos will no longer be eligible to receive any future milestone payments relating to filgotinib in Europe. However, Gilead remains responsible for commercial activities outside of Europe and Galapagos will remain eligible to receive tiered royalty percentages ranging from 20% to 30% on Gilead’s global net sales of filgotinib outside of Europe and future development and regulatory milestone-based payments of up to $275 million and sales-based milestone payments of up to $600 million.

Work with us

Combining internal and external innovation

We are looking for new licensing opportunities and partnerships to build our pipeline. Do you want to pioneer for patients, together?

Latest news

Visit our newsroom to stay informed about our progress

Our history

What started as a dream to pioneer for patients, crystalized in an international biotechnology company

Investor hub

Looking for information about our company, our stock and our financials?